Physician profile
David Spencer
NPI 1134143605
$14,344.55
in general payments reported to CMS, 2019-2025
38 companies · $1,941 in 2025
The $1,941 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,008 · 2020: $1,129 · 2021: $2,122 · 2022: $2,246 · 2023: $2,454 · 2024: $2,444 · 2025: $1,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,216 · Education: $490 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,216.44 |
| Education | $489.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $132.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,906.60 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Sun Pharmaceutical Industries INC. | $1,413.73 | 2019-2025 | Winlevi, Ilumya |
| Genzyme Corporation | $1,279.43 | 2019-2025 | |
| Pfizer INC. | $1,249.59 | 2019-2025 | |
| Janssen Biotech, INC. | $855.36 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $766.26 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $691.66 | 2019-2025 | |
| Amgen INC. | $665.29 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $609.12 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $531.69 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $364.53 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $348.55 | 2021-2024 | Opzelura |
| Mayne Pharma Commercial LLC | $335.43 | 2019-2021 | |
| Ucb, INC. | $332.32 | 2019-2025 | Bimzelx |
| Dermavant Sciences, INC. | $230.05 | 2023-2024 | Vtama |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $228.60 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $223.93 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $208.21 | 2019-2021 | |
| Almirall LLC | $147.85 | 2019-2021 | |
| Galderma Laboratories, L.P. | $144.00 | 2019-2025 | Nemluvio |
| Celgene Corporation | $123.60 | 2019 | |
| Epi Health, LLC | $118.86 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $80.64 | 2023 | Ycanth |
| Organon LLC | $75.35 | 2025 | Vtama |
| Sandoz INC. | $52.41 | 2020-2024 | Hyrimoz |
| Paratek Pharmaceuticals, INC. | $48.88 | 2022 | |
| Merck Sharp & Dohme LLC | $47.08 | 2019 | |
| Biofrontera INC. | $42.76 | 2022-2025 | |
| Sebela Pharmaceuticals INC. | $35.32 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $33.48 | 2021 | |
| Journey Medical Corporation | $32.62 | 2021-2022 | |
| Convatec INC. | $32.61 | 2024 | |
| Taro Pharmaceuticals USA, INC. | $21.38 | 2019 | |
| Mimedx Group, INC. | $20.90 | 2024 | |
| Botanix Sb INC | $20.57 | 2025 | Sofdra |
| Dermira, INC. | $14.73 | 2019 | |
| Allergan, INC. | $11.16 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.